Genitourinary Cancers

  • Robert G. Parker
  • Nora A. Janjan
  • Michael T. Selch
Part of the Medical Radiology book series (MEDRAD)


In 2001, about 292,900 genitourinary cancers were diagnosed in the United States [1]. The anatomic sites were prostate, 198,100; urinary bladder, 54,000; kidney and renal pelvis, 30,800; testes, 7200; ureter and other urinary organs, 2400; and penis and other male genital organs, 1200.


Prostate Cancer Renal Cell Carcinoma Bladder Cancer Seminal Vesicle Gleason Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Devesa SS, Blot WJ, Stone BJ et al (1995) Recent cancer trends in the United States. J Natl Cancer Inst 87: 175–182PubMedCrossRefGoogle Scholar
  2. 2.
    Greenlee RT, Murray T, Bolden S et al (2000) Cancer statistics, 2000. CA Cancer J Clin 50: 7–33PubMedCrossRefGoogle Scholar
  3. 3.
    Breslow N, Chan CW, Dhom G et al (1977) Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer 20: 680–688PubMedCrossRefGoogle Scholar
  4. 4.
    The American Cancer Society (2001) Cancer facts and figuresGoogle Scholar
  5. 5.
    Perez CA (1997) Prostate. In: Perez CA, Brady LW (eds) Principles and practice of radiation oncology, 3rd edn. Lippincott-Raven, Philadelphia, pp 1583–1694Google Scholar
  6. 6.
    Pienta KJ, Demers R, Hoff M et al (1995) Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tri-county area 1973 to 1987. Urology 45: 93–101PubMedCrossRefGoogle Scholar
  7. 7.
    Natarajan N, Murphy GP, Mettlin C (1989) Prostate cancer in blacks. An update from the American College of Surgeons. Patterns of care studies. J Surg Oncol 40: 232–236Google Scholar
  8. 8.
    Ross RK, Coetzee GA, Reichardt J et al (1995) Does the racial-ethnic variation in prostate cancer risk have a hormonal basis? Cancer 75: 1778–1782CrossRefGoogle Scholar
  9. 9.
    Aprikian AG, Bazinet M, Plante M et al (1995) Family history and the risk of prostatic carcinoma in a high-risk group of urological patients. J Urol 154: 404–406PubMedCrossRefGoogle Scholar
  10. 10.
    Narod SA, Dypont A, Cusan L et al (1995) The impact of family history on early detection of prostate cancer. Nat Med 1: 99–101PubMedCrossRefGoogle Scholar
  11. 11.
    Glantz GM (1964) Cirrhosis and carcinoma of the prostatic gland. J Urol 91: 291–293PubMedGoogle Scholar
  12. 12.
    Robson MC (1966) Cirrhosis and prostatic neoplasms. Geriatrics 21: 150–154PubMedGoogle Scholar
  13. 13.
    Barrett-Commor E, Garland C, McPhillips JB et al (1990) A prospective, population-based study of androstenedione, estrogens and prostatic cancer. Cancer Res 50: 169–173Google Scholar
  14. 14.
    Nomura A, Heilbrun LK, Stemmerman GN et al (1988) Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 48: 3515–3517PubMedGoogle Scholar
  15. 15.
    Meikle AW, Smith JA, Stringham JD (1987) Production, clearance and metabolism of testosterone in men with prostatic cancer. Prostate 10: 25–31PubMedCrossRefGoogle Scholar
  16. 16.
    Ross RK, Bernstein L, Judd H et al (1986) Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76: 45–48PubMedGoogle Scholar
  17. 17.
    Ross RK, Bernstein L, Lobo RA et al (1992) 5-Alphareductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339: 887–889Google Scholar
  18. 18.
    Armenian HK, Lilienfeld AM, Diamond EL et al (1974) Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. Lancet 2: 115–117Google Scholar
  19. 19.
    Greenwald P, Kirmss V, Polan AK et al (1974) Cancer of the prostate among men with benign prostatic hyperplasia. J Natl Cancer Inst 53: 335–340PubMedGoogle Scholar
  20. 20.
    Giovannuci E, Tosteson TD, Speizer FE et al (1993) A retrospective cohort study of vasectomy and prostate cancer in US men. JAMA 269: 878–882CrossRefGoogle Scholar
  21. 21.
    Hsing AW, McLaughton JK, Schuman LM et al (1990) Diet, tobacco use and fatal prostate cancer. Cancer Res 50: 6836–6840PubMedGoogle Scholar
  22. 22.
    Kaul L, Hekmat MY, Kovi J et al (1987) The role of diet in prostate cancer. Nutr Cancer 9: 123–128PubMedCrossRefGoogle Scholar
  23. 23.
    Gronberg TW, Damber L, Damber JE (1996) Total food consumption and body mass index in relation to prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data. J Urol 155: 969–974PubMedCrossRefGoogle Scholar
  24. 24.
    Bean MA,Yatani R, Liu PI et al (1973) Prostatic carcinoma at autopsy in Hiroshima and Nagasaki. Cancer 32: 498–506CrossRefGoogle Scholar
  25. 25.
    McNeal JE (1981) Zonal anatomy of the prostate. Prostate 2: 35–49PubMedCrossRefGoogle Scholar
  26. 26.
    Pisansky TM, Lee WR, Lawton CH, Bosturck DG (2000) Prostate cancer. In: Gunderson LL, Tepper JE (eds) Clinical radiation oncology, 1st edn. Churchill-Livingstone, Edinburgh, pp 762–819Google Scholar
  27. 27.
    Moore KL (1992) Clinically oriented anatomy, 3rd edn. Williams and Wilkins, BaltimoreGoogle Scholar
  28. 28.
    Walsh PC, Schlegel PN (1988)Radical pelvic surgery with preservation of sexual function. Ann Surg 208: 391–400Google Scholar
  29. 29.
    Peterson RO (1986) Neoplastic disorders in urologic pathology. Lippincott, PhiladelphiaGoogle Scholar
  30. 30.
    Leewansangtong S, Crawford D (2001)Prostate.In: Haskell CM (ed) Cancer treatment, 5th edn. Saunders, Philadelphia, pp 806–828Google Scholar
  31. 31.
    Gleason DF (1966) Classification of prostatic carcinoma. Cancer Chemother Rep 50: 125–128PubMedGoogle Scholar
  32. 32.
    Brawn PN, Ayala AG, von Eschenbach AC et al (1982) Histologic grading study of prostate adenocarcinoma: the development of a new system and comparison with other methods, a preliminary study. Cancer 49: 525–532PubMedCrossRefGoogle Scholar
  33. 33.
    Broders AC (1922) Epithelioma of the genitourinary organs. Ann Surg 75: 574–604PubMedCrossRefGoogle Scholar
  34. 34.
    Mostofi FK (1975) Grading of prostatic carcinoma. Cancer Chemother Rep 59: 111–117PubMedGoogle Scholar
  35. 35.
    McNeal JE, Bostwick DG (1986) Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 17: 64–71PubMedCrossRefGoogle Scholar
  36. 36.
    McNeal JE (1981) Origin and development of carcinoma of the prostate. Prostate 2: 35–49PubMedCrossRefGoogle Scholar
  37. 37.
    Jewett HJ (1980) Radical perineal prostatectomy for palpable, clinically localized nonobstructive cancer: experience at the Johns Hopkins Hospital 1909–1963. J Urol 124: 492–494PubMedGoogle Scholar
  38. 38.
    Andriole GL, Pomas SH, Catalona WJ (1992) The implications of focal well-differentiated prostate cancer in men with elevated serum PSA and palpably normal prostates. J Urol 147 [Suppl 4]: 442AGoogle Scholar
  39. 39.
    Breslow N, Chan CW, Dhom G et al (1977) Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer 20: 680–688PubMedCrossRefGoogle Scholar
  40. 40.
    Oesterling JE, Suman VJ, Zincke H et al (1994) PSAdetected (clinical stage T1C or B1) prostate cancer. Urol Clin North Am 20: 293–302Google Scholar
  41. 41.
    Epstein JI, Walsh PC, Carmichael M et al (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1C) prostate cancer. JAMA 271: 68–73CrossRefGoogle Scholar
  42. 42.
    Ohori M, Scardino PT, Lapin SL et al (1993) The mechanism and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol 17: 1252–1261PubMedCrossRefGoogle Scholar
  43. 43.
    Partin AW, Kattan MW, Subong ENP et al (1997) Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277: 1445–1451Google Scholar
  44. 44.
    Bostwick DG, Qian J, Bergstralk E et al (1996) Predication of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 155: 1361–1367PubMedCrossRefGoogle Scholar
  45. 45.
    D’Amico AV, Whittington R, Malkowicz SE et al (1994) A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 30: 293–302PubMedCrossRefGoogle Scholar
  46. 46.
    Ohori M, Wheeler TM, Kattan MW et al (1995) Prognostic significance of positive margins in radical prostatectomy specimens. J Urol 154: 1818–1824PubMedCrossRefGoogle Scholar
  47. 47.
    Partin AW, Yoo J, Carter HB et al (1993) The use of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110–114PubMedGoogle Scholar
  48. 48.
    Roach M, Marquez C, Yuo HS et al (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. J Radiat Oncol Biol Phys 28: 33–37CrossRefGoogle Scholar
  49. 49.
    Whitmore WF Jr (1984) Natural history and staging of prostate cancer. Urol Clin North Am 11: 205–220PubMedGoogle Scholar
  50. 50.
    American Joint Committee on Cancer (1997) Manual for staging cancer. Lippincott, PhiladelphiaGoogle Scholar
  51. 51.
    Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23: 273–279PubMedCrossRefGoogle Scholar
  52. 52.
    Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr, Walsh PC (1987) Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 138: 92–98PubMedGoogle Scholar
  53. 53.
    Elgamal A-Z, Ectors NL, Sunardi, Widyaputra S et al (1996) Detection of prostate-specific antigen in pancreas and salivary glands. A potential impact on prostate cancer overestimation. J Urol 156: 464–468Google Scholar
  54. 54.
    Wang MC, Valenzuela LA, Murphy GP et al (1979) Purification of a human prostatic-specific antigen. Invest Urol 17: 159–163PubMedGoogle Scholar
  55. 55.
    Brawer MK, Schifman RB, Ahmann ER et al (1988) The effect of digital rectal examination on serum levels of prostatic-specific antigen. Arch Pathol Lab Med 112: 1110–1112PubMedGoogle Scholar
  56. 56.
    Matzkin H, Laufer M, Chen J et al (1996) Effect of elective prolonged urethral catheterization on serum prostate-specific antigen concentration. Urology 48: 63–66PubMedCrossRefGoogle Scholar
  57. 57.
    Oesterling JE, Rice DC, Glenski WJ et al (1993) Effect of cystoscopy, prostate biopsy and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 42: 276–282PubMedCrossRefGoogle Scholar
  58. 58.
    Yuan JJ, Coplen DE, Petros JA et al (1992) Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate-specific antigen levels. J Urol 147: 810–814PubMedGoogle Scholar
  59. 59.
    Tchetgen M-B, Song JT, Strawderman M et al (1996) Ejaculation increases the serum prostate-specific antigen concentration. Urology 47: 511–516PubMedCrossRefGoogle Scholar
  60. 60.
    Stamey TA, Kabalin JN, McNeal JE et al (1989) Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II: radical prostatectomy treated patients. J Urol 141: 1076–1083PubMedGoogle Scholar
  61. 61.
    Lange PH (1990) Prostate-specific antigen for staging prior to surgery and for early detection of recurrence after surgery. Urol Clin North Am 17: 813–817PubMedGoogle Scholar
  62. 62.
    Keetch DW, McMurtry JM, Smith DS et al (1996) Prostate-specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostate biopsies. J Urol 156: 428–431PubMedCrossRefGoogle Scholar
  63. 63.
    Hanks GE, Hanlon LA, Lee WR et al (1996) Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34: 549–553PubMedCrossRefGoogle Scholar
  64. 64.
    Zagars GK, Pollack A, Kavadi VS et al (1995) Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32: 293–306PubMedCrossRefGoogle Scholar
  65. 65.
    Arcangeli CG, Sheperd DL, Smith DS et al (1996) Correlation of percent free PSA with pathologic features of prostatic carcinomas (abstract). J Urol 55 [Suppl]: 415AGoogle Scholar
  66. 66.
    Catalona WJ, Smith DS, Wolfert RL et al (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214–1220PubMedCrossRefGoogle Scholar
  67. 67.
    Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383PubMedCrossRefGoogle Scholar
  68. 68.
    Leibel SA, Hanks GE, Kramer S (1984) Patterns of care outcome studies: Results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 10: 401–409Google Scholar
  69. 69.
    Zagars GK, Pollack A, von Eschenbach AC (1997) Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate-specific antigen era. Cancer 79: 1370–1380PubMedCrossRefGoogle Scholar
  70. 70.
    Moul JW, Douglas TH, McCarthy WF et al (1996) Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 155: 1667–1673PubMedCrossRefGoogle Scholar
  71. 71.
    Optenberg S, Thompson I, Friedrichs P et al (1996) Race, treatment and long-term survival from prostate cancer in an equal-access medical delivery system (abstract). J Urol 155 [Suppl]: 486AGoogle Scholar
  72. 72.
    Gilliland FD, Becker TM, Key CR et al (1994) Contrasting trends of prostate cancer incidence and mortality in New Mexico’s Hispanics, non-Hispanic whites, American Indians and blacks. Cancer 73: 2192–2199Google Scholar
  73. 73.
    Kattan MW, Stapleton AM, Wheeler TM et al (1997) Evaluation of a nomogram to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79: 528–537PubMedCrossRefGoogle Scholar
  74. 74.
    Paulson DF, Robertson CN (1991) Positive margins. Is adjunctive radiation therapy indicated? Acta Oncol 30: 263–265PubMedCrossRefGoogle Scholar
  75. 75.
    Blute MI, Bostwick DG, Seay TM et al (1998) Pathologic classification of prostate carcinoma. The impact of margin status. Cancer 82: 902–908Google Scholar
  76. 76.
    Ohori M, Scardino PT, Lapin SL et al (1993) The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol 17: 1252–1261PubMedCrossRefGoogle Scholar
  77. 77.
    Diaz A, Roach M, Marquez C et al (1994) Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 30: 323–329PubMedCrossRefGoogle Scholar
  78. 78.
    Pisansky TM, Blute ML, Suman VJ et al (1996) Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys 36: 585–591PubMedCrossRefGoogle Scholar
  79. 79.
    Jewett BH, Eggleston JC, Yawn DH (1972) Radical prostatectomy in the management of carcinoma of the prostate: probable causes of some therapeutic failures. J Urol 107: 1034–1040PubMedGoogle Scholar
  80. 80.
    Stamey TA, McNeal JE, Freiha FS, Redwine E (1988) Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 139: 1235–1241PubMedGoogle Scholar
  81. 81.
    Schmid HP, Mihatsch MJ, Hering F et al (1997) Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy. Eur Urol 31: 11–16PubMedGoogle Scholar
  82. 82.
    Cheng L, Bergstrolh EJ, Cheville JC (1998) Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 22: 1491–1500PubMedCrossRefGoogle Scholar
  83. 83.
    Rifkin MD, Choi H (1988) Implications of small, peripheral hypoechoic lesions in endorectal US of the prostate. Radiology 166: 619–622PubMedGoogle Scholar
  84. 84.
    Flanigan RC, Catalona WJ, Rechie JP et al (1994) Accuracy of digital rectal examination and transrectal ultra-sonography in localizing prostate cancer. J Urol 152: 1506–1509PubMedGoogle Scholar
  85. 85.
    Rifkin MD, Zerhouni EA, Gastonis CA et al (1990) Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multiinstitutional cooperative trial. N Engl J Med 323: 621–626Google Scholar
  86. 86.
    Salo JO, Kivisaari L, Rannikko S, Lehtonen T (1987) Computerized tomography and transrectal ultrasound in the assessment of local extension of prostatic cancer before radical retropubic prostatectomy. J Urol 137: 435–438PubMedGoogle Scholar
  87. 87.
    Terris NM, McNeal JE, Freiha FS, Stamey TA (1993) Efficacy of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J Urol 149: 1035–1039PubMedGoogle Scholar
  88. 88.
    Clements R (1996) The changing role of transrectal ultrasound in the diagnosis of prostate cancer. Clin Radiol 51: 671–676PubMedCrossRefGoogle Scholar
  89. 89.
    Chelsky MJ, Schnall MD, Seidman EJ, Pollack HM (1993) Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J Urol 150: 391–395PubMedGoogle Scholar
  90. 90.
    Perrotti M, Kaufman RP Jr, Jennings TA et al (1996) Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer. Is it accurate? J Urol 156: 106–109PubMedCrossRefGoogle Scholar
  91. 91.
    Kurhanewicz J, Vigneron DB, Hricak H et al (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7 cm3) spatial resolution. Radiology 198: 795–805PubMedGoogle Scholar
  92. 92.
    Yu KK, Scheidler J, Hricak H et al (1999) Prostate cancer: prediction of extra-capsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213: 481–488PubMedGoogle Scholar
  93. 93.
    Chybowski FM, Keller JJ, Bergstralh EJ, Osterling JE (1991) Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer. Prostate-specific antigen is superior to all other clinical parameters. J Urol 145: 313–318Google Scholar
  94. 94.
    Oesterling JE, Martin SK, Bergsralh EJ et al (1993) The use of prostatic specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269: 57–60PubMedCrossRefGoogle Scholar
  95. 95.
    Sullivan L, Copeland D, Cohen L et al (1994) Ability of serum PSA to predict normal bone scans in untreated prostate cancer (abstract). J Urol 151 [Suppl 1]: 341AGoogle Scholar
  96. 96.
    Perez CA (1995) Carcinoma of the prostate: a model for management under impending health care system reform: 1994 RSNA annual oration in radiation oncology. Radiology 196: 309–322PubMedGoogle Scholar
  97. 97.
    Sands ME, Zagars GK, Pollack A, von Eschenbach AC (1994) Serum prostate-specific antigen, clinical stage, pathologic grade and the incidence of nodal metastases in prostate cancer. Urology 44: 215–220PubMedCrossRefGoogle Scholar
  98. 98.
    Petros JA, Catalona WJ (1992) Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J Urol 147: 15741575Google Scholar
  99. 99.
    Kerbl K, Clayman RV, Petros JA et al (1993) Staging pelvic lymphadenectomy for prostate cancer: a comparison of laparoscopic and open techniques. J Urol 150: 396–399PubMedGoogle Scholar
  100. 100.
    Steiner MS, Morton RA, Walsh PC (1991) Impact of anatomical radical prostatectomy on urinary continence. J Urol 145: 512–515PubMedGoogle Scholar
  101. 101.
    Walsh PC, Donker PJ (1982) Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128: 492–497PubMedGoogle Scholar
  102. 102.
    Stamey TA, Yang N, Hay AR et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909–916PubMedCrossRefGoogle Scholar
  103. 103.
    Begg CB, Reidel ER, Bach PB et al (2002) Variations in morbidity after radical prostatectomy. N Engl J Med 346: 1138–1194PubMedCrossRefGoogle Scholar
  104. 104.
    Del Regato JA, Trailings AH, Pittman DD (1993) Twenty-year follow-up of patients with inoperable cancer of the prostate (stage c) treated by radiotherapy: report of a National Cooperative Study. Int J Radiat Oncol Biol Phys 26: 197–201PubMedCrossRefGoogle Scholar
  105. 105.
    Bagshaw MA, Ray GR, Cox RA (1985) Radiotherapy of prostatic carcinoma: long-or short-term efficacy ( Stanford University experience ). Urology 25: 17–23Google Scholar
  106. 106.
    Lawton CA, Cox JD, Gilsch C et al (1992) Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? Analysis of RTOG studies 7506 and 7706. Cancer 69: 2761–2766PubMedCrossRefGoogle Scholar
  107. 107.
    Zelefsky MJ, Fuks Z, Happersett L et al (2000) Clinical 126. experience with intensity modulated radiation therapy ( IMRT) in prostate cancer. Radiother Oncol 55: 241–249Google Scholar
  108. 108.
    Bagshaw MA, Kaplan ID, Cox RS (1993) Radiation therapy for localized disease. Cancer 71: 939–952PubMedCrossRefGoogle Scholar
  109. 109.
    Kuban DA, El-Mandi MA, Schellhamer PF (1987) Effect of local-tumor control on distant metastasis and survival in 128. prostate adenocarcinoma. Urology 30: 420–426PubMedCrossRefGoogle Scholar
  110. 110.
    American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat 129. Oncol Biol Phys 37: 1035–1041Google Scholar
  111. 111.
    Kuban DA, El Mandi AM, Schellhamer PF (1995) Prostate-specific antigen for pretreatment prediction and 130. posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 32: 307–316PubMedCrossRefGoogle Scholar
  112. 112.
    Schneider S, Schweitzer V, Parker RG, Bycott PW (1986) 131. The prognostic value of PSA levels in prostate cancer treated with primary radiation therapy: the UCLA experience, 1988–1992. Am J Clin Oncol 19: 65–72Google Scholar
  113. 113.
    Bagshaw MA (1995) Comments on the treatment of 132. prostate cancer by conventional radiation therapy: an analysis of long-term outcome, regarding Zietman et al. Int J Radiat Oncol Biol Phys 32: 541–543 133.Google Scholar
  114. 114.
    Hanks GE, Martz KL, Diamond JJ (1988) The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15: 1299–1305 134.Google Scholar
  115. 115.
    Levitt SH, Khan FM (2001) The rush to judgement: does the evidence support the enthusiasm over three-dimensional conformal radiation therapy and dose escalation in 135. the treatment of prostate cancer? Int J Radiat Oncol Biol Phys 51: 871–879PubMedCrossRefGoogle Scholar
  116. 116.
    Pasteau O (1911) Traitement du cancer de la prostate par 136. le radium. Rev Mal Nutr 363Google Scholar
  117. 117.
    Whitmore WF Jr, Hilaris B, Grabstald H (1972) Retropubic implantation of iodine 125 in the treatment of prostate cancer. J Urol 108: 918–920 137.Google Scholar
  118. 118.
    Wallner K, Roy J, Zelefsky M et al (1994) Short-term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys 30: 405–409 138.Google Scholar
  119. 119.
    Ragde H, Blasko J, Grimm PD et al (1997) Brachytherapy for clinically localized prostate cancer: Results at 7- and 8-year follow-up. Semin Surg Onc 13: 438–443CrossRefGoogle Scholar
  120. 120.
    Meier R, Mark R, St Royal L, Tran L, Colburn G, Parker RG (1992) Postoperative radiation therapy after radical 139. prostatectomy for prostate cancer. Cancer 70: 1960–1966PubMedCrossRefGoogle Scholar
  121. 121.
    Elias S, Parker RG, Gallardo D, Law J (1997) Adjuvant radiation therapy after radical prostatectomy for carcinoma of the prostate. Am J Clin Oncol 20: 120–124 140.Google Scholar
  122. 122.
    Bostwick DG, Egbert BM, Fajard LF (1982) Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 6: 541–551PubMedCrossRefGoogle Scholar
  123. 123.
    Crook JM, Perry GA, Robertson S et al (1995) Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 45: 624–631PubMedCrossRefGoogle Scholar
  124. 124.
    Prestidge BR, Hoak DC, Grimm PD et al (1997) Posttreatment biopsy results following interstitial brachytherapy in early stage prostate cancer. Int J Radiat Oncol Biol Phys 37: 31–39PubMedCrossRefGoogle Scholar
  125. 125.
    Rogers E, Ohori M, Kassabian VS et al (1995) Salvage prostatectomy: outcome measured by serum prostate-specific antigen levels. J Urol 153: 104–110PubMedCrossRefGoogle Scholar
  126. 126.
    Fitzpatrick PJ, Rider W (1976) Half-body radiotherapy. Int J Radiat Oncol Biol Phys 1: 197–207PubMedCrossRefGoogle Scholar
  127. 127.
    Tochner Z, Weshler Z, Rigel S, Fuks Z (1982) Fractionated hemiskeleton irradiation for multifocal skeleton pain in patients with widespread carcinomatous metastasis to bone (abstract). Int J Radiat Onc Biol Phys 8: 128Google Scholar
  128. 128.
    Zelefsky MJ, Scher HI, Forman JD et al (1989) Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single-dose and fractionated regimes. Int J Radiat Oncol Biol Phys 17: 1281–1285PubMedCrossRefGoogle Scholar
  129. 129.
    Laing AH, Ackery DM, Bayly RK et al (1991) Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 64: 816–822PubMedCrossRefGoogle Scholar
  130. 130.
    Hanks GE, Schultheiss TE, Hunt MA et al (1995) Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 31: 25–29PubMedCrossRefGoogle Scholar
  131. 131.
    Pilepich MV, Asbell SO, Krall JM et al (1987) Correlation of radiotherapeutic parameters and treatment related morbidity: analysis of RTOG study 77–06. Int J Radiat Oncol Biol Phys 13: 1007–1012PubMedCrossRefGoogle Scholar
  132. 132.
    Perez CA, Michalski J, Lockett MA (1995) Radiation therapy in the treatment of localized prostate cancer: an alternative to an emerging consensus. Mod Med 82: 696–704Google Scholar
  133. 133.
    Lee WR, Schultheiss TE, Hanlon AL et al (1996) Urinary incontinence following external beam radiotherapy for clinically localized prostate cancer. Urology 48: 95–99PubMedCrossRefGoogle Scholar
  134. 134.
    Banker FL (1988) The preservation of potency after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 15: 219–220PubMedCrossRefGoogle Scholar
  135. 135.
    Chaikin DC, Broderick GA, Malloy TR et al (1996) Erectile dysfunction following minimally invasive treatment for prostate cancer. Urology 48: 100–104PubMedCrossRefGoogle Scholar
  136. 136.
    Huggins C, Hodges CV (1941) Studies of prostatic cancer 1. The effects of castration, of estrogen and androgen injections on serum phosphases in metastatic carcinoma of the prostate. Cancer Res 1: 293–307Google Scholar
  137. 137.
    Griffiths K, Eaton CL, Harper ME et al (1994) Hormonal treatment of advanced disease–some newer aspects. Semin Oncol 21: 672–687PubMedGoogle Scholar
  138. 138.
    Pilepich MV, Krall JM, Al-Sarraf M et al (1995) Androgen deprivation with radiation therapy alone for locally advanced prostatic carcinoma. A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616–623Google Scholar
  139. 139.
    Bolla M, Gonzalez D, Wasde P et al (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295–300PubMedCrossRefGoogle Scholar
  140. 140.
    Dalesio O, Vantineren H, Denis L et al (1995) Maximum androgen blockade in advanced prostate cancer. An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 346: 265–269CrossRefGoogle Scholar
  141. 141.
    Reiner WG, Scott WW, Eggleston JE et al (1979) Long-term survival after hormonal therapy for stage D prostatic cancer. J Urol 122: 183–184PubMedGoogle Scholar
  142. 142.
    Litwin MS, Hays RD, Fink A et al (1995) Quality of life outcomes in men treated for localized prostate cancer. JAMA 273: 129–135PubMedCrossRefGoogle Scholar
  143. 143.
    Wei JT, Dunn RL, Sandler HM et al (2002) Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20: 557–566PubMedCrossRefGoogle Scholar
  144. 1.
    American Cancer Society (2001) Cancer facts and figuresGoogle Scholar
  145. 2.
    Tolley DA, Hargrave TB, Smith PH et al (1988) Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer ( Urological Cancer Working Party ). Br Med J 296: 1759–1761Google Scholar
  146. 3.
    Leewansangtong S, Crawford ED (2001) Bladder, renal pelvis and ureters. In: Haskell CM (ed) Cancer treatment, 5th edn. Saunders, Philadelphia, pp 828–853Google Scholar
  147. 4.
    Morrison AS, Buring JE, Verhoek WG et al (1984) An international study of smoking and bladder cancer. J Urol 131: 650–654PubMedGoogle Scholar
  148. 5.
    Waterhouse J (1982) Cancer incidence in five continents, vol 4. International Agency for Research in Cancer of the World Health Organization, LyonGoogle Scholar
  149. 6.
    Morris AD, Zietman AL, Kaufman DS, Shipley WU (2000) Bladder cancer. In: Gunderson LL, Tepper JE (eds) Clinical radiation oncology, 1st edn. Churchill-Livingstone, EdinburghGoogle Scholar
  150. 7.
    Moore KL (1992) Clinically oriented anatomy, 3rd edn. Williams and Wilkins, Baltimore MD, pp 276–277Google Scholar
  151. 8.
    Parsons JT, Zlotecki RA (1998) Bladder. In: Perez CA, Brady LW (eds) Principles and practice of radiation oncology, 3rd edn. Lippincott-Raven, Philadelphia, pp 1543–1571Google Scholar
  152. 9.
    Riddle PR, Chisholm GD, Trott PA, Pugh RC (1975) Flat carcinoma-in-situ of the bladder. Br J Urol 47: 829–833PubMedCrossRefGoogle Scholar
  153. 10.
    Utz DC, Hanash KA, Farrow GM (1970) The plight of the patient with carcinoma-in-situ of the bladder. J Urol 103: 160–164PubMedGoogle Scholar
  154. 11.
    Smith G, Elton RA, Beynon LL et al (1983) Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br J Urol 55: 665–669PubMedCrossRefGoogle Scholar
  155. 12.
    Whitmore WF Jr (1983) Management of invasive bladder neoplasms. Semin Urol 1: 34–41PubMedGoogle Scholar
  156. 13.
    Jewett HJ, Strong GH (1946) Infiltrating carcinoma of the bladder: relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J Urol 55: 366–372PubMedGoogle Scholar
  157. 14.
    Marshall VF, Holden J, Ma KT (1956) Survival of patients with bladder carcinoma treated by simple segmental resection. Cancer 9: 568–571PubMedCrossRefGoogle Scholar
  158. 15.
    Hermanek P (1987) UICC-TNM classification of malignant tumors, 4th edn. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  159. 16.
    Bosl GL (1991) American Society of Clinical Oncology Educational Handbook. Society of Clinical Oncology, ChicagoGoogle Scholar
  160. 17.
    Soto EA, Friedell GH, Tiltman AJ (1977) Bladder cancer as seen in giant histologic sections. Cancer 39: 447–455PubMedCrossRefGoogle Scholar
  161. 18.
    Rundle JS, Hart AJ, McGeorge A et al (1982) Squamous cell carcinoma of the bladder: a review of 114 patients. Br J Urol 54: 522–526PubMedCrossRefGoogle Scholar
  162. 19.
    Mostofi FK, Davis CJ Jr, Sesterhenn IA (1988) Pathology of tumors of the urinary tract. In: Skinner DG, Lieskovsky G (eds) Diagnosis and management of genitourinary cancer. Saunders, Philadelphia, pp 83–117Google Scholar
  163. 20.
    Blomjous CEM, Vos W, de Voogt HJ et al (1989) Small cell carcinoma of the urinary bladder: a clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer 64: 1347–1357PubMedCrossRefGoogle Scholar
  164. 21.
    Heney NM, Ahmed S, Flanagan MJ et al (1983) Superficial bladder cancer: progression and recurrence. J Urol 130: 1083–1086PubMedGoogle Scholar
  165. 22.
    Carbin BE, Ekman P, Gustafson H et al (1991) Grading of human urothelial carcinoma based on nuclear atypia and mitotic frequency. I. Histological description. J Urol 145: 968–971Google Scholar
  166. 23.
    Pollack A, Zagars GK, Swanson DA (1994) Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 30: 267277Google Scholar
  167. 24.
    Fung CY, Shipley WU, Young RH et al (1991) Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol 9: 1533–1542PubMedGoogle Scholar
  168. 25.
    Quilty PM, Kerr GR, Duncan W (1986) Prognostic indices for bladder cancer: an analysis of patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 9: 311–321CrossRefGoogle Scholar
  169. 26.
    Gospodarowicz MK, Hawkins NV, Rawlings GA et al (1989) Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 142: 1448–1454PubMedGoogle Scholar
  170. 27.
    Shipley WU, Zietman AL (1999) Bladder cancer. Refresher Course 105, 41st annual scientific meeting of the American Society for Therapeutic Radiology and Oncology, 31 Oct 1999, San Antonio, TexasGoogle Scholar
  171. 28.
    Sauer R, Berkenhage S, Kuhn R et al (1998) Efficacy of radiochemotherapy with platin derivatives compared with radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 40: 121–127PubMedCrossRefGoogle Scholar
  172. 29.
    Lerner SP, Skinner DG, Lieskovsky G et al (1993) The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol 149: 758–765PubMedGoogle Scholar
  173. 30.
    Ghersi D, Stewart LA, Parmar MKB et al (1995) Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br J Urol 75: 206–213CrossRefGoogle Scholar
  174. 31.
    Greven KM, Spera JA, Solin LJ et al (1992) Local control after cystectomy alone in bladder carcinoma. Cancer 69: 2767–2770PubMedCrossRefGoogle Scholar
  175. 32.
    Frazier HA, Robertson JE, Paulson DF (1992) Complications of radical cystectomy and urinary diversion: a retrospective review of 675 cases in 2 decades. J Urol 148: 1401–1405PubMedGoogle Scholar
  176. 33.
    Schlegel PN, Walsh PC (1987) Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol 138: 1402–1406PubMedGoogle Scholar
  177. 34.
    Cummings K, Mason J, Correa R et al (1978) Segmental resection in the management of bladder carcinoma. J Urol 119: 56–58PubMedGoogle Scholar
  178. 35.
    Lindahl F, Jorgensen P, Equad K (1984) Partial cystectomy for transitional cell carcinoma of the bladder. Scand J Nephrol 18: 125–129CrossRefGoogle Scholar
  179. 36.
    Buschke F, Cantril ST, Parker HM (1950) Supervoltage roentgentherapy, lst edn. Thomas, Springfield Ill, pp 151–199Google Scholar
  180. 37.
    Horwich A, Pendlebury S, Dearnley DP (1995) Organ conservation in bladder cancer. Eur J Cancer 31 [Suppl 5]: 208–212CrossRefGoogle Scholar
  181. 38.
    Naslund I, Nilsson B, Littbrand B (1994) Hyperfractionated radiotherapy of bladder cancer: a 10-year follow-up of a randomized trial. Acta Oncol 33: 397–402PubMedCrossRefGoogle Scholar
  182. 39.
    Kachnic LA, Kaufman DS, Griffin PP et al (1997) Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15: 1022–1029PubMedGoogle Scholar
  183. 40.
    Houssett M, Dufour E, Malard-Durtux C et al (1997) Concomitant 5-flurouricil-cisplatin and bifractionated split course radiation therapy for invasive bladder cancer (abstract no. 1139). Proc Am Soc Clin Oncol 16Google Scholar
  184. 41.
    Shipley WU, Winter KA, Lee R et al (1997) Initial results of RTOG 89–03: a phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy (abstract 41). Int J Radiat Oncol Biol Phys 39: 155CrossRefGoogle Scholar
  185. 42.
    Barringer BS (1952) Radium therapy of bladder cancer, retrospect and prospect. J Urol 68: 280–282PubMedGoogle Scholar
  186. 43.
    Carver JH (1959) Interstitial radiation in the treatment of selected cases of cancer of the bladder. Br J Urol 31: 313–316CrossRefGoogle Scholar
  187. 44.
    Moonen LM, Horenblas S, Van der Voet JC et al (1994) Bladder conservation in selected T2–T3a bladder carcinoma using combination therapy of surgery and iridium-193 implantation. Br J Urol 74: 322–327PubMedCrossRefGoogle Scholar
  188. 45.
    Montie JE, Whitmore WF, Grabstald HM, Yagoda A (1983) Unresectable carcinoma of the bladder. Cancer 51: 2351 2355Google Scholar
  189. 46.
    Holmhang S, Borghede G (1996) Early complications and survival following short-term palliative radiotherapy in invasive bladder carcinoma. J Urol 155: 100–102CrossRefGoogle Scholar
  190. 47.
    Fossa SD, Hosbach G (1991) Short-term moderate-dose radiotherapy of advanced bladder carcinoma. Acta Oncol 30: 735–738PubMedGoogle Scholar
  191. 48.
    Silber I, Bowler WT, Cordonnier JJ (1969) Palliative treatment of carcinoma of the urinary bladder. Cancer 3: 586–588CrossRefGoogle Scholar
  192. 49.
    McLaren DB, Morrey D, Mason MD (1997) Hypofractionated radiotherapy for muscle-invasive bladder cancer in the elderly. Radiother Oncol 43: 171–174PubMedCrossRefGoogle Scholar
  193. 50.
    Salminen E (1992) Unconventional fractionation for palliative radiotherapy of urinary bladder cancer. Acta Oncol 31: 449–454PubMedCrossRefGoogle Scholar
  194. 51.
    Chan RC, Bracken RB, Johnson DE (1979) Single-dose whole pelvis megavoltage irradiation for palliative control of hematuria or ureteral obstruction. J of Urol 122: 750–751Google Scholar
  195. 52.
    Wijkstrom H, Naslund I, Ekman P, Kohler C, Nilsson B, Norming U (1991) Short-term radiotherapy as palliative treatment in patients with transitional cell bladder cancer. Br J Urol 67: 74–78PubMedCrossRefGoogle Scholar
  196. 53.
    Duchesne GM, Bolger JJ, Griffiths GO et al (2000) A randomized trial of hypofractionation schedules of palliative radiotherapy in the management of bladder carcinoma: results of Medical Research Council Trial BA09. Int J Radiat Oncol Biol Phys 47: 379–388PubMedCrossRefGoogle Scholar
  197. 54.
    Rostom AY, Tahir S, Gershuny AR et al (1996) Once weekly irradiation for carcinoma of the bladder. Int J Radiat Oncol Biol Phsy 35: 289–292CrossRefGoogle Scholar
  198. 1.
    American Cancer Society (2001) Cancer facts and figures. Atlanta, GAGoogle Scholar
  199. 2.
    Kosary CL, McLaughlin JK (1993) Kidney and renal pelvis. In: Miller BA Ries LAG, Hankey BF et al (eds) SEER cancer statistics review, 1973–1990. National Cancer Institute, Bethesda (NIH publication number 93–2789, XI-1-XI-22)Google Scholar
  200. 3.
    Buskirk SJ, Smalley SR, Zincke H (2000) Kidney and ureteral cancer. In: Gunderson LL, Tepper JE (eds) Clinical radiation oncology, 1st edn. Churchill Livingstone, New York, pp 863–878Google Scholar
  201. 4.
    Grawitz VP (1883) Die sogenannten lipome de niere. Pathol Anat 93: 39Google Scholar
  202. 5.
    Pisani P, Parkin DM, Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 55: 891–903PubMedCrossRefGoogle Scholar
  203. 6.
    Chow WH, Devesa SS, Warren JL, Fraumeni JF (1999) Rising incidence of renal cell cancer in the United States. JAMA 281: 1628–1631PubMedCrossRefGoogle Scholar
  204. 7.
    Miller BA ed (1996) Racial/ethnic patterns of cancer in the United States, 1988–1992. National Cancer Institute, Bethesda, pp 56–60 (NIH publication number 96–4104 )Google Scholar
  205. 8.
    Moore KL (1992) Clinically oriented anatomy, 3rd edn. Williams and Williams, Baltimore, pp 218–221Google Scholar
  206. 9.
    Schwartz LH, Richard J, Buffat L et al (1994) Kidney mobility during respiration. Radiother Oncol 32: 84–86PubMedCrossRefGoogle Scholar
  207. 10.
    Yu MC, Mack TM, Hanisch R et al (1986) Cigarette smoking, obesity, diuretic use and coffee consumption as risk factors for renal cell carcinoma.Google Scholar
  208. 11.
    Mellemgaard A, Engholm G, McLaughlin JK, Olsen JH (1994) Risk factors for renal cell carcinoma in Denmark: role of socioeconomic status, tobacco use, beverages and family history. Cancer Causes Control 5: 105–113PubMedCrossRefGoogle Scholar
  209. 12.
    Lornoy W, Becaus S, deVleeschouwer M (1986) Renal cell cell carcinoma. carcinoma, a new complication of analgesic nephropathy. Lancet 1: 1271–1272PubMedCrossRefGoogle Scholar
  210. 13.
    Lindblad P, Mellengaard A, Schlekofer B et al (1995) national renal cell cancer study. V. Reproductive factors, gynecologic operations and exogenous hormones. Int J Cancer 61: 192–198Google Scholar
  211. 14.
    Kanzlaric D, Barmeir E, Luscieti P et al (1987) Renal car- cinoma after retrograde pyelography with Thorotrast. Am J Roentgenol 148: 897–898CrossRefGoogle Scholar
  212. 15.
    Michalski JM (1998) Kidney, renal pelvis and ureter. In: Perez CA, Brady LW (eds) Principles and practice of radia tion oncology, 3rd edn. Lippincott-Raven, Philadelphia, pp 1525–1541Google Scholar
  213. 16.
    Van den Berg E, van der Hout AH, Oosterhuis JW et al (1993) Cytogenic analysis of epithelial renal-cell tumors: relationship with a new histo-pathological classification. Int J Cancer 55: 223–227PubMedCrossRefGoogle Scholar
  214. 17.
    Storkel S, van den Berg E (1995) Morphological classifica tion of renal cancer. World J Urol 13: 153–158PubMedCrossRefGoogle Scholar
  215. 18.
    Thoenes W, Storkel S, Rumpelt HJ (1986) Histopathol therapy. ogy and classification of renal cell tumors (adenomas, oncocytomas, and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 181: 125–143PubMedCrossRefGoogle Scholar
  216. 19.
    Motzer RJ, Bander NJ, Nanus DM (1996) Renal-cell carci-noma. N Engl J Med 335: 865–875PubMedCrossRefGoogle Scholar
  217. 20.
    Flocks RH, Kadesky MC (1958) Malignant neoplasms of the kidney: an analysis of 353 patients followed five years 79: 196Google Scholar
  218. 21.
    Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297–301PubMedGoogle Scholar
  219. 22.
    Fleming ID, Cooper JS, Henson DE et al (1997) Kidney. In: American Joint Committee on Cancer (ed) Manual for staging of cancer.(abstract). Gastroenterology 40: 694Google Scholar
  220. 23.
    Gitlitz BJ, Hoffman D MJ, Figlin RA, Belldegrun AS (2001) Kidney. In: Haskell CM (ed) Cancer treatment, 5th edn. Saunders, Philadelphia, pp 863–880Google Scholar
  221. 24.
    Ritchie AWS, Chisholm GD (1983) The natural history of renal carcinoma. Semin Oncol 10: 390–400PubMedGoogle Scholar
  222. 25.
    Waters WB, Richie JP (1979) Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J Urol 122: 306–309PubMedGoogle Scholar
  223. 26.
    Muggia FM (1990) Overview of cancer-related hypercalce- mia: epidemiology and etiology. Semin Oncol 17: 3–9PubMedGoogle Scholar
  224. 27.
    Laski ME, Vugrin D (1987) Paraneoplastic syndrome in hypernephroma. Semin Nephrol 7: 123–130PubMedGoogle Scholar
  225. 28.
    Lindop GBM, Fleming S (1984) Renin in renal cell carci- noma–an immunocytochemical study using an antibody to pure human renin. J Clin Pathol 37: 27–31PubMedCrossRefGoogle Scholar
  226. 29.
    Jobe BA, Bierman MH, Mezzacapa FJ (1993) Hyperglyce- mia as a paraneoplastic endocrinopathy in renal cell car cinoma: a case report and review of the literature. Nebr Med J 78: 348–351Google Scholar
  227. 30.
    Berger L, Sinkoff MWL (1957) Systemic manifestations of hypernephroma. Am J Med 22: 791–796PubMedCrossRefGoogle Scholar
  228. 31.
    Stauffer MH (1961) Lippincott-Raven, Philadelphia J Natl Cancer Inst 77: Nephrogenic hepatosplenomegaly 351–365Google Scholar
  229. 32.
    Novick AC, Strem SB (1998) Surgery of the kidney. In: Walsh PC, Patik AB, Vaughan ED et al (eds) Campbell’s urology, 7th edn. Saunders, Philadelphia, pp 2973–3061Google Scholar
  230. 33.
    Couillard DR, deVere-White RW (1993) Surgery of renal Urol Clin North Am 20: 263–275Google Scholar
  231. 34.
    Sokoloff MH, de Kernon JB, Figlin RA, Belledgrun A (1996) Current management of renal cell carcinoma. CA Inter¬ Cancer J Clin 46: 284–302CrossRefGoogle Scholar
  232. 35.
    Wunderlich H, Reichelt O, Schumann S et al (1998) Neph ron-sparing surgery for renal cell carcinoma 4 cm or less in diameter: indicated or undertreated? J Urol 159: 1465–1469PubMedCrossRefGoogle Scholar
  233. 36.
    Provet J, Tessler A, Brown J et al (1991) Partial nephrec tomy for renal cell carcinoma: indications, results and implications. J Urol 145: 472–476PubMedGoogle Scholar
  234. 37.
    Belldegrun A, Tsui KH, de Kernion JB et al (1999) Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 TNM tumor staging. J Clin Oncol 17: 2868–2875PubMedGoogle Scholar
  235. 38.
    D’Armiento M, Damiano R, Feleppa B et al (1997) Elective conservative surgery for renal carcinoma versus radical nephrectomy: a prospective study. Br J Urol 79: 15–19PubMedCrossRefGoogle Scholar
  236. 39.
    Rabinovitch RA, Zelefsky MJ, Gaynor JJ et al (1994) Pat terns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic J Clin Oncol 12: 206–212Google Scholar
  237. 40.
    Kao GD, Malkowicz SB, Whittington R et al (1994) Locally advanced renal cell carcinoma: Low complication rate and efficacy of postnephrectomy radiation therapy planned with CT. Radiology 193: 725–730Google Scholar
  238. 41.
    Stein M, Kuten A, Halperin J et al (1992) The value of postoperative irradiation in renal cell cancer. Radiother Oncol 24: 41–44PubMedCrossRefGoogle Scholar
  239. 42.
    Van der Werf-Messing B (1973) Proceedings: carcinoma of or more. J Urol the kidney. Cancer 32: 1056–1061Google Scholar
  240. 43.
    Jurusela H, Malino K, Alfthan O, Oravisto KJ (1977) Pre operative irradiation in the treatment of renal adenocar cinoma. Scand J Urol Nephrol 11: 277–281CrossRefGoogle Scholar
  241. 44.
    Alexander E III, Moriarty TM, Davis RB et al (1995) Ste reotactic radiosurgery for the definitive noninvasive treat ment of brain metastases. J Natl Cancer Inst 87: 34–49PubMedCrossRefGoogle Scholar
  242. 45.
    Fuller BG, Kaplan ID, Adler J et al (1992) Stereotactic radiosurgery for brain metastases: the importance of adjuvant whole brain irradiation. Int J Radiat Oncol Biol Phys 23: 413–418PubMedCrossRefGoogle Scholar
  243. 46.
    Wronski M, Maor MH, Davis BJ et al (1997) External beam radiation of brain metastases from renal carcinoma: a ret rospective study of 119 patients from the MD Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37: 753–759PubMedCrossRefGoogle Scholar
  244. 47.
    Althausen P, Althausen A, Jennings LC, Mankin HJ (1997) Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 80: 1103–1109PubMedCrossRefGoogle Scholar
  245. 48.
    Onufrey V, Mohiuddin M (1985) Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 11: 2007–2009PubMedCrossRefGoogle Scholar
  246. 49.
    Halperin EC, Harisiadis L (1983) The role of radiation therapy in the management of metastatic renal cell carci noma. Cancer 51: 614–617PubMedCrossRefGoogle Scholar
  247. 50.
    Yagoda A, Petrylak D, Thompson S (1993) Cytotoxic che motherapy for advanced renal cell carcinoma. Urol Clin North Am 20: 303–321PubMedGoogle Scholar
  248. 51.
    Bloom HJG (1971) Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer. Br J Cancer 25: 250–265PubMedCrossRefGoogle Scholar
  249. 52.
    Quesada JR, Swanson DA, Trindade A, Gutterman JU (1983) Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 43: 940–947PubMedGoogle Scholar
  250. 53.
    De Kernion J, Sarna G, Figlin R et al (1983) The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 130: 1063–1066Google Scholar
  251. 54.
    Soori GS, Schulof RS, Stark JJ et al (1999) Continuous infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study. Cancer Invest 17: 379–384PubMedCrossRefGoogle Scholar
  252. 55.
    Fossa SD, Raabe N, Moe B (1989) Recombinant interferon alpha with or without vinblastine in metastatic renal carcinoma: results of a randomized phase II study. Br J Urol 64: 468–471PubMedCrossRefGoogle Scholar
  253. 56.
    Aulitzky WE, Lerche J, Thews A et al (1994) Low-dose gamma interferon therapy is ineffective in renal cell carcinoma patients with large tumor burdens. Eur J Cancer 30A: 940–945CrossRefGoogle Scholar
  254. 57.
    Rosenberg SA (1988) Immunotherapy of cancer using IL-2. Immunol Today 9: 58–67PubMedCrossRefGoogle Scholar
  255. 58.
    Rosenberg SA, Lotze MT, Yang JC et al (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–484PubMedCrossRefGoogle Scholar
  256. 1.
    American Cancer Society (2001) Cancer facts and figures, New YorkGoogle Scholar
  257. 2.
    Hainsworth JD, Greco FA (2001) Testis. In: Haskell CM (ed) Cancer treatment. Saunders, Philadelphia, pp 880–897Google Scholar
  258. 3.
    Thomas G, Williams SD (1997) Testis. In: Perez CA, Brady LW (eds) Principles and practice of radiation oncology, 3rd edn. Lippincott-Raven, Philadelphia, pp 1695–1715Google Scholar
  259. 4.
    Basmajian JV (1980) Grant’s method of anatomy, 10th edn. Williams and Wilkins, Baltimore MD, pp 133–135Google Scholar
  260. 5.
    Dixon F, Moore R (1953) Tumors of the male sex organs. In: Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington DC, p 31Google Scholar
  261. 6.
    Mostofi F, Sobin L (1977) International histological classification of tumors of testes. World Health Organization, GenevaGoogle Scholar
  262. 7.
    Warde PR, Sturgeon JFD, Gospodarowicz MK (2000) Testicular oncology In: Gunderson LL, Tepper JE (eds) Clinical radiation oncology, 1st edn. Churchill-Livingstone, New York, pp 844–862Google Scholar
  263. 8.
    Mostofi FK (1973) Proceedings: testicular tumors. Epidemiologic, etiologic, and pathologic features. Cancer 32: 1186–1201PubMedCrossRefGoogle Scholar
  264. 9.
    Ray B, Hajdu SI, Whitmore WF Jr (1974) Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer 33: 340–348PubMedCrossRefGoogle Scholar
  265. 10.
    Union Internationale Contre le Cancer (1987) TNM classification of malignant tumours. Springer, Berlin Heidelberg New YorkGoogle Scholar
  266. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (1992) Testis. In: Manual for staging of cancer, 4th edn. Lippincott, Philadelphia, pp 195–201Google Scholar
  267. 12.
    Thomas GM (1990) Consensus statement on the investigation and management of testicular seminoma. In: Newling DW, Jones WG (eds) Prostate cancer and testicular cancer. (EORTG genito-urinary group monograph 7 ) Wiley-Liss, New YorkGoogle Scholar
  268. 13.
    Horwich A, Bell J (1994) Mortality and cancer incidence following radiotherapy for seminoma of the testis. Radiother Oncol 30: 193–198PubMedCrossRefGoogle Scholar
  269. 14.
    Warde PR, Gospodarowicz M, Goodman P et al (1994) Late relapse in patients on surveillance for stage I testicular seminoma. Adv Brosci 19: 193–195Google Scholar
  270. 15.
    Thomas GM, Rider WD, Dembo AJ et al (1982) Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys 8: 165–174PubMedCrossRefGoogle Scholar
  271. 16.
    Loehrer PJ, Birch R Sr, Williams SD et al (1987) Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 5: 1212–1220PubMedGoogle Scholar
  272. 17.
    Bosl GJ, Geller NL, Cerrincione C et al (1983) Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3403–3407PubMedGoogle Scholar
  273. 18.
    Hoskin P, Dilly S, Easton D et al (1986) Prognostic factors in stage I nonseminomatous germ cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 4: 1031–1036PubMedGoogle Scholar
  274. 19.
    Klepp O, Olsson AM, Henrickson H et al (1990) Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 8: 509–518Google Scholar
  275. 20.
    Lange PH, Fraley EE (1977) Serum alpha feta protein and human chorionic gonadotropin in the treatment of patients with testicular tumours. Urol Clin North Am 4: 393–406PubMedGoogle Scholar
  276. 21.
    Bosl G, Gluckman R, Geller N et al (1986) VAB-6. An effective chemotherapy regime for patients with germ cell tumors. J Clin Oncol 4: 1493–1499Google Scholar
  277. 22.
    Ellerbroek NA, Tran LM, Selch MT, Taylor JMG, Parker RG (1988) Testicular seminoma: a study of 103 cases treated at UCLA. Am J Clin Oncol 11: 93–99PubMedCrossRefGoogle Scholar
  278. 23.
    Hamilton CR, Horwick A, Bliss JM, Peckham MJ (1987) Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. Radiother Oncol 10: 85–90PubMedCrossRefGoogle Scholar
  279. 24.
    Baniel J, Foster RS, Einhorn LH, Donohue JP (1995) Late relapse of clinical stage I testicular cancer. J Urol 154: 1370–1372PubMedCrossRefGoogle Scholar
  280. 25.
    Warde P, Gospodarowicz MK, Panzarella T et al (1995) Stage I testicular seminoma. Results of adjuvant irradiation and surveillance. J Clin Oncol 13: 2255–2266Google Scholar
  281. 26.
    Peckham MJ, Hamilton CR, Horwich A, Hendry WF (1987) Surveillance after orchiectomy for stage I seminoma of the testis. Br J Urol 59: 343–347PubMedCrossRefGoogle Scholar
  282. 27.
    Thomas GM (1993) Surveillance in Stage I seminoma of the testis. Urol Clin North Am 20: 85–91PubMedGoogle Scholar
  283. 28.
    Von der Maase H, Specht L, Jacobsen GK et al (1993) Surveillance following orchiectomy for stage I seminoma of the testis. Eur J Cancer 29A: 1931–1934CrossRefGoogle Scholar
  284. 29.
    Sharda NN, Kinsella TJ, Ritter MA (1996) Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early stage testicular seminoma. J Clin Oncol 14: 2933–2939PubMedGoogle Scholar
  285. 30.
    Bucholz TA, Walden TL,Prestidge BR (1998) Cost-effectiveness of post-treatment surveillance after radiation therapy for early stage seminoma. Cancer 82: 1126–1133Google Scholar
  286. 31.
    Mencel PJ, Motzer RJ, Mazundar M et al (1994) Advanced seminoma: treatment, results, survival and prognostic factors in 142 patients. J Clin Oncol 12: 120–126PubMedGoogle Scholar
  287. 32.
    Shultz SM, Einhorn LH, Conces DJ Jr et al (1989) Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 7: 1497–1503Google Scholar
  288. 33.
    Puc HS, Heelan R, Mazundan M et al (1996) Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14: 454–460PubMedGoogle Scholar
  289. 34.
    Parker RG, Holyoke JB (1960) Tumors of the testis. Am J Roentgenol 83: 43–65Google Scholar
  290. 35.
    Samuels M, Johnson E, Holyoke P (1975) Continuous infusion bleomycin therapy with vinblastine in stage III testicular neoplasms. Cancer Chemother Rep 59: 563–570PubMedGoogle Scholar
  291. Vugrin D, Herr H, Whitmore WJ Jr et al (1981) VAB-6 combination chemotherapy in disseminated cancer of the testis. Ann Intern Med 95: 59–61CrossRefGoogle Scholar
  292. 37.
    Einhorn L, Donohue J (1977) Cis-diamine dichoroplatinum, vinblastine + bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293–298PubMedCrossRefGoogle Scholar
  293. 38.
    Read G, Stenning S, Cullen M et al (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10: 1762–1768Google Scholar
  294. 39.
    Williams SD, Stablein DM, Einhorn LH et al (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433–1438PubMedCrossRefGoogle Scholar
  295. 40.
    Bokemeyer C, Nowak P, Haupt A et al (1997) Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 15: 1449–1454PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Robert G. Parker
    • 1
  • Nora A. Janjan
    • 2
  • Michael T. Selch
    • 1
  1. 1.Department of Radiation Oncology, UCLA School of MedicineUniversity of California, Los AngelesLos AngelesUSA
  2. 2.Department of Radiation OncologyM.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations